Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTAINASDAQ:ETONNASDAQ:IOBTNASDAQ:NGM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTAIBioXcel Therapeutics$1.96+1.6%$1.63$1.17▼$21.92$11.88M0.041.22 million shs78,653 shsETONEton Pharmaceuticals$14.53+0.3%$16.58$3.22▼$21.48$389.56M1.18257,806 shs243,255 shsIOBTIO Biotech$1.51+1.0%$1.25$0.66▼$1.73$99.15M0.36283,565 shs182,872 shsNGMNGM Biopharmaceuticals$1.54$1.55$0.60▼$4.69$128.53M1.271.47 million shsN/AMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTAIBioXcel Therapeutics+1.55%-3.45%+43.07%+20.25%-88.66%ETONEton Pharmaceuticals+0.31%+4.05%-15.94%+22.78%+341.49%IOBTIO Biotech+1.01%+1.69%-0.33%+52.92%+33.19%NGMNGM Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTAIBioXcel Therapeutics4.3279 of 5 stars3.34.00.04.51.81.70.6ETONEton Pharmaceuticals2.539 of 5 stars3.53.00.00.01.41.70.6IOBTIO Biotech2.7073 of 5 stars3.73.00.00.00.62.50.6NGMNGM Biopharmaceuticals1.7166 of 5 stars0.00.00.04.70.03.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTAIBioXcel Therapeutics 2.67Moderate Buy$42.602,073.47% UpsideETONEton Pharmaceuticals 3.00Buy$29.67104.25% UpsideIOBTIO Biotech 3.33Buy$9.33520.16% UpsideNGMNGM Biopharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IOBT, NGM, BTAI, and ETON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025ETONEton PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $35.005/16/2025ETONEton PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $26.005/14/2025IOBTIO BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/14/2025ETONEton PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$26.00 ➝ $28.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTAIBioXcel Therapeutics$2.27M5.23N/AN/A($30.01) per share-0.07ETONEton Pharmaceuticals$39.01M9.99N/AN/A$0.94 per share15.45IOBTIO BiotechN/AN/AN/AN/A$0.71 per shareN/ANGMNGM Biopharmaceuticals$4.42M29.10N/AN/A$1.80 per share0.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTAIBioXcel Therapeutics-$59.60M-$13.55N/AN/AN/A-2,163.18%N/A-83.80%8/5/2025 (Estimated)ETONEton Pharmaceuticals-$3.82M-$0.18N/A29.05N/A-9.49%-3.15%-1.08%8/4/2025 (Estimated)IOBTIO Biotech-$95.49M-$1.49N/AN/AN/AN/A-162.55%-125.08%8/12/2025 (Estimated)NGMNGM Biopharmaceuticals-$142.38M-$1.72N/AN/AN/A-3,223.34%-77.85%-67.76%N/ALatest IOBT, NGM, BTAI, and ETON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ETONEton Pharmaceuticals$0.09$0.07-$0.02-$0.06$14.33 million$17.28 million5/12/2025Q1 2025BTAIBioXcel Therapeutics-$2.72-$1.50+$1.22-$1.50$0.35 million$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTAIBioXcel TherapeuticsN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AIOBTIO BiotechN/AN/AN/AN/AN/ANGMNGM BiopharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTAIBioXcel TherapeuticsN/A1.481.45ETONEton Pharmaceuticals1.231.971.43IOBTIO BiotechN/A2.322.32NGMNGM BiopharmaceuticalsN/A7.797.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTAIBioXcel Therapeutics30.68%ETONEton Pharmaceuticals27.86%IOBTIO Biotech54.76%NGMNGM Biopharmaceuticals75.74%Insider OwnershipCompanyInsider OwnershipBTAIBioXcel Therapeutics21.20%ETONEton Pharmaceuticals16.03%IOBTIO Biotech4.80%NGMNGM Biopharmaceuticals35.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTAIBioXcel Therapeutics906.06 million4.77 millionOptionableETONEton Pharmaceuticals2026.82 million22.52 millionOptionableIOBTIO Biotech3065.88 million62.72 millionNot OptionableNGMNGM Biopharmaceuticals13883.46 million53.50 millionOptionableIOBT, NGM, BTAI, and ETON HeadlinesRecent News About These CompaniesNGM Biopharmaceuticals Advances in Cancer Cachexia Treatment with NGM120 StudyJune 27, 2025 | tipranks.comHundreds of tech, biotech, oil, school workers lose Bay Area jobsMay 17, 2025 | eastbaytimes.comENGM Bio slims down in strategic pivot, cutting 75% of staff and halting a midstage liver disease programMay 13, 2025 | fiercebiotech.comFNGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the...February 24, 2025 | macaubusiness.comMBiosion, Inc. Appoints Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion USFebruary 19, 2025 | finance.yahoo.comNGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical OfficerFebruary 4, 2025 | finance.yahoo.comMerck takes stake in NGM amid flurry of pharma dealsDecember 29, 2024 | pharmaphorum.comPcricket win win casinoDecember 29, 2024 | bwsmartcities.businessworld.inBA venture firm breathes new life into an old NGM drugDecember 20, 2024 | biopharmadive.comBNGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/ß-Klotho Agonist Drug CandidateDecember 19, 2024 | tmcnet.comVC firm pens $608M biobucks deal to redirect NGM's MASH drug to rare diseaseDecember 19, 2024 | fiercebiotech.comFNGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug CandidateDecember 19, 2024 | finance.yahoo.comCountywide layoffs coolNovember 4, 2024 | smdailyjournal.comSGlobal Pancreatic Cancer Market Ready to Hit USD 7,541.09 Million by 2033 with a Noteworthy CAGR of 13.5%October 21, 2024 | fmiblog.comFNGM steps up in Greater NewcastleOctober 16, 2024 | bankingday.comBVEGFR-2 Antagonists Clinical Trial Pipeline Insights Featuring 25+ Companies | DelveInsightOctober 8, 2024 | finance.yahoo.comNGM Energy fits Starlink, virtual machines and cybersecurity with NavarinoSeptember 26, 2024 | thedigitalship.comTRenal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightSeptember 24, 2024 | finance.yahoo.comPlanet Mars, explainedSeptember 24, 2024 | nationalgeographic.comNMachu PicchuSeptember 20, 2024 | nationalgeographic.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIOBT, NGM, BTAI, and ETON Company DescriptionsBioXcel Therapeutics NASDAQ:BTAI$1.96 +0.03 (+1.55%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$1.99 +0.03 (+1.53%) As of 07/3/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Eton Pharmaceuticals NASDAQ:ETON$14.52 +0.05 (+0.31%) As of 07/3/2025 03:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.IO Biotech NASDAQ:IOBT$1.50 +0.02 (+1.01%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$1.46 -0.04 (-2.99%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.NGM Biopharmaceuticals NASDAQ:NGMNGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case How a Government Loan Changes the Game for Plug Power Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
